Pharmaceutisch Weekblad

, Volume 10, Issue 3, pp 101–116 | Cite as

Etoposide and teniposide

Bioanalysis, metabolism and clinical pharmacokinetics
  • J. J. M. Holthuis
Review Articles


Etoposide (VP 16-213) and teniposide (VM 26) are semisynthetic epipodophyllotoxin derivatives active against a variety of tumours. The clinical efficacy has led to an increasing interest in these compounds. This review presents information on the mechanism of action, biochemical pharmacology, bioanalysis, metabolism and pharmacokinetics of etoposide and teniposide.


Chemistry Chromatography Etoposide Immunoassay Metabolism Podophyllotoxin Pharmacokinetics Teniposide 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kuhn M, Keller-Juslen C, Von Wartburg A. Partial synthese von 4′-demethylepipodophyllotoxin. Helv Chim Acta 1969;52:944–7.PubMedGoogle Scholar
  2. 2.
    Kuhn M, Von Wartburg A. über ein neues Glykosidierungsverfahren. II. Glykoside des 4′-demethylepipodophyllotoxins. Helv Chim Acta 1969;52:948–55.PubMedGoogle Scholar
  3. 3.
    Keller-Juslen C, Kuhn M, Von Wartburg A. Synthesis and antimycotic activity of glycosidic lignan derivatives related to podophyllotoxin. J Med Chem 1971;14:936–40.PubMedGoogle Scholar
  4. 4.
    Kelly MG, Hartwell JL. The biological effects and the chemical composition of podophyllin. A review. J Natl Cancer Inst 1954;14:967–1010.PubMedGoogle Scholar
  5. 5.
    Holthuis JJM. Bioanalysis, electrochemistry and pharmacokinetics of etoposide, teniposide and metabolites. Utrecht: State University of Utrecht, 1985. Dissertation.Google Scholar
  6. 6.
    Holthuis JJM, Van Oort WJ, Römkens FMGM, Renema J, Zuman P. Electrochemistry of podophyllotoxin derivatives. Part 1. Oxidation mechanism of etoposide (VP 16-213). J Electroanal Chem 1985;184:317–29.Google Scholar
  7. 7.
    Holthuis JJM, Vendrig DEMM, Van Oort WJ, Zuman P. Electrochemistry of podophyllotoxin derivatives. Part n. Oxidation of teniposide and some epipodophyllotoxin derivatives. J Electroanal Chem 1987;220:101–24.Google Scholar
  8. 8.
    Beijnen JH, Holthuis JJM, Kerkdijk HG, et al. Degradation kinetics of etoposide in aqueous solution. J Int Pharm 1988;41:169–78.Google Scholar
  9. 9.
    Dow LW, Sinkule JA, Look AT, Horvath A, Evans WE. Comparative cytotoxic and cytokinetic effects of the epipodophyllotoxins 4′-demethylepipodophyllotoxin-9-(4,6-O-2-ethylidene-d-glucopyranoside) and 4′-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-Β-d-glucopyranoside) and their metabolites on human leukemic lymphoblasts. Cancer Res 1983;43:5699–706.PubMedGoogle Scholar
  10. 10.
    Chow D, Shah J, Chen JR. Stability-indicating highperformance liquid chromatography of etoposide at various pH conditions using a reversed-phase octyl column. J Chromatogr 1987;396:217–23.PubMedGoogle Scholar
  11. 11.
    Floor BJ, Klein AE, Muhammad N, Ross D. Stabilityindicating liquid chromatographic determination of etoposide and benzyl alcohol in injectable formulations. J Pharm Sci 1985;74:197–200.PubMedGoogle Scholar
  12. 12.
    Loike JD, Brewer CF, Sternlicht H, Gensler WJ, Horwitz SB. Structure-activity study of the inhibition of microtubule assemblyin vitro by podophyllotoxin and its congeners. Cancer Res 1978;38:2688–93.PubMedGoogle Scholar
  13. 13.
    Loike JD. VP 16-213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity. Cancer Chemother Pharmacol 1982;7:103–11.PubMedGoogle Scholar
  14. 14.
    Loike JD, Horwitz SB. Effects of podophyllotoxin and VP-16-213 on microtubule assemblyin vitro and nucleoside transport in HeLa cells. Biochemistry 1976;15:5435–43.PubMedGoogle Scholar
  15. 15.
    Allen L. The role of drug disposition kinetics on cellular transport of the antineoplastic agent VM-26. Drug Metab Rev 1978;8:119–35.PubMedGoogle Scholar
  16. 16.
    Yalowich J, Goldman ID. Analysis of the inhibitory effects of VP-16-213 (etoposide) and podophyllotoxin on thymidine transport and metabolism in Ehrlich ascites tumor cellsin vitro. Cancer Res 1984;44:984–9.PubMedGoogle Scholar
  17. 17.
    Loike JD, Horwitz SB. Effect of VP 16-213 on the intracellular degradation of DNA in HeLa cells. Biochemistry 1976;15:5443–8.PubMedGoogle Scholar
  18. 18.
    Long BH, Musial ST, Brattain MC. Comparison of the cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP 16-213 and VM 216. A quantitative structure activity relationship. Biochemistry 1984;23:1183–8.PubMedGoogle Scholar
  19. 19.
    Wozniak AJ, Ross WE. DNA damage as a basis for 4′-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-Β-d-glucopyranoside) (Etoposide) cytotoxicity. Cancer Res 1983;43:120–4.PubMedGoogle Scholar
  20. 20.
    Van Maanen JMS. Metabolic activation of the antitumor agent VP-16-213. Amsterdam: Free University, 1988. Dissertation.Google Scholar
  21. 21.
    Van Maanen JMS, De Ruiter C, Kootstra PR, et al. Inactivation of X174 DNA by the ortho-quinone derivative or its reduction product of the antitumor agent VP 16-213. Eur J Cancer Clin Oncol 1985;21:1215–8.PubMedGoogle Scholar
  22. 22.
    Van Maanen JMS, De Ruiter C, Kootstra PR, De Vries J, Pinedo HM. Free radical formation from the antineoplastic agent VP 16-213. Free Rad Res Commun 1986;1:263–72.Google Scholar
  23. 23.
    Wozniak AJ, Glisson BS, Hande KR, Ross WE. Inhibition of etoposide-induced DNA damage and cytotoxicity in L 1210 cells by dehydrogenase inhibitors and other agents. Cancer Res 1984;44:626–32.PubMedGoogle Scholar
  24. 24.
    Ross W, Rowe T, Glisson B, Yalowich J, Liu L. Role of topoisomerase 11 mediating epipodophyllotoxininduced DNA cleavage. Cancer Res 1984;44:5857–60.PubMedGoogle Scholar
  25. 25.
    Glisson BS, Smallwood SE, Ross WE. Characterization of VP-16-induced DNA damage in isolated nuclei from L1210 cells. Biochim Biophys Acta 1984;783:74–9.PubMedGoogle Scholar
  26. 26.
    Rowe T, Kupfer G, Ross W. Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage. Biochem Pharmacol 1985;4:2483–7.Google Scholar
  27. 27.
    O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE. Etoposide (VP-16-213). Current status of an active anticancer drug. N Engl J Med 1985;312:692–700.PubMedGoogle Scholar
  28. 28.
    Postmus PE, De Vries EGE, De Vries-Hospers HG, et al. Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation. A dose escalation study. Eur J Cancer Clin Oncol 1984;20:777–82.PubMedGoogle Scholar
  29. 29.
    Greco FA, Johnson DH, Wolff SN, et al. A phase 11 study of high dose VP 16-213 and autologous bonemarrow transplantation for refractory germinal neoplasms. Proc Am Soc Clin Oncol 1983;19:138.Google Scholar
  30. 30.
    Hande KR, Wedlund PJ, Noone RM, Wilkinson GR, Greco FA, Wolff SN. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res 1984;44:379–82.PubMedGoogle Scholar
  31. 31.
    O'Dwyer PJ, Alonso MT, Leyland-Jones B, Marsoni S. Teniposide: a review of 12 years of experience. Cancer Treat Rep 1984;68:1455–66.PubMedGoogle Scholar
  32. 32.
    De Vries EGE, Mulder NH, Postmus PE, Vriesendorp R, Willemse PHB, Sleyfer DTh. High-dose teniposide for refractory malignancies: a phase 1 study. Cancer Treat Rep 1986;70:595–8.PubMedGoogle Scholar
  33. 33.
    Schmoll H. Review of etoposide single-agent activity. Cancer Treat Rep 1982;9:21–30.Google Scholar
  34. 34.
    Postmus PE, Mulder NH, Sleyfer DTh, Meinesz AF, Vriesendorp R, De Vries EGE. High dose etoposide for refractory malignancies: a phase 1 study. Cancer Treat Rep 1984;68:1471–4.PubMedGoogle Scholar
  35. 35.
    Sinkule JA, Evans WE. High-performance liquid Chromatographic analysis of the semisynthetic epipodophyllotoxins etoposide and teniposide using electrochemical detection. J Pharm Sci 1984;73:164–8.PubMedGoogle Scholar
  36. 36.
    Evans WE, Sinkule JA, Crom WR, Dow L, Look AT, Rivera G. Pharmacokinetics of teniposide (VM 26) and etoposide (VP16-213) in children with cancer. Cancer Chemother Pharmacol 1982;7:147–50.PubMedGoogle Scholar
  37. 37.
    Holthuis JJM, Postmus PE, Van Oort WJ, et al. Pharmacokinetics of high dose etoposide (VP 16-213). Eur J Cancer Clin Oncol 1986;22:1149–55.PubMedGoogle Scholar
  38. 38.
    Postmus PE, Holthuis JJM, Haaxma-Reiche H, et al. Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration. J Clin Oncol 1984;2:215–20.PubMedGoogle Scholar
  39. 39.
    Van Maanen JMS, Holthuis JJM, Gobas F, et al. Role of bioactivation in covalent binding of VP 16-213 to rat liver and HeLa cell microsomal proteins. Proc Am Assoc Cancer Res 1983;24:319.Google Scholar
  40. 40.
    Van Maanen JMS, Van Oort WJ, Pinedo HM.In vitro andin vivo metabolism of VP 16-213 in the rat. Eur J Cancer Clin Oncol 1982;18:885–90.PubMedGoogle Scholar
  41. 41.
    Creaven PJ, Allen LM. EPEG, a new antineoplastic epipodophyllotoxin. Clin Pharmacol Ther 1975;18:221–6.PubMedGoogle Scholar
  42. 42.
    Allen LM, Creaven PJ. Comparison of the human pharmacokinetics of VM 26 and VP 16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives. Eur J Cancer 1975;11:697–707.PubMedGoogle Scholar
  43. 43.
    Creaven PJ, Allen LM. PTG, a new antineoplastic epipodophyllotoxin. Clin Pharmacol Ther 1975;18:227–33.PubMedGoogle Scholar
  44. 44.
    Allen LM, Marcks C, Creaven PJ. 4′-demethyl-epipodophyllic acid-9-(4,6-O-ethylidene-Β-d-glucopyranoside) the major urinary metabolite of VP 16-213 in man. Proc Am Assoc Cancer Res 1976;17:6.Google Scholar
  45. 45.
    Sinkule JA, Hutson P, Hayes FA, Etcubanas E, Evans W. Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. Cancer Res 1984;44:3109–13.PubMedGoogle Scholar
  46. 46.
    Strife RJ, Jardine I, Colvin M. Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high performance liquid chromatography. J Chromatogr 1980;182:211–20.PubMedGoogle Scholar
  47. 47.
    Colombo T, D'Incalci M, Donelli MG, et al. Metabolic studies of a podophyllotoxin derivative (VP16) in the isolated perfused liver. Xenobiotica 1985;15:343–50.PubMedGoogle Scholar
  48. 48.
    Holthuis JJM, Van Oort WJ, Hulshoff A. Determination of the glucuronide(s) of the antineoplastic agent etoposide. In: Reid E, ed. Methodological surveys in biochemistry and analysis. New York: Plenum Press, 1986;389–93. (Reid E, Scales B, Wilson ID, eds. Bioactive analytes, including CNS drugs, peptides, and enantiomers. Vol. 16.)Google Scholar
  49. 49.
    Rossi C, Zucchetti M, Sessa C, Urso R, Mangioni C, D'Incalci M. Pharmacokinetic study of VM 26 given as a prolonged rv infusion to ovarian cancer patients. Cancer Chemother Pharmacol 1984;13:211–4.PubMedGoogle Scholar
  50. 50.
    Sinha BK, Tush MA, Kalanaraman B. Microsomal interactions and inhibition of lipid peroxidation by etoposide (VP 16-213): implications for mode of action. Biochem Pharmacol 1985;34:2036–40.PubMedGoogle Scholar
  51. 51.
    Haim N, Roman J, Nemec J, Sinha BK. Peroxidative free radical formation ando-demethylation of etoposide (VP 16) and teniposide (VM 26). Biochem Biophys Res Commun 1986;135:215–20.PubMedGoogle Scholar
  52. 52.
    Haim N, Nemec J, Roman J, Sinha BK.In vitro metabolism of etoposide (VP 16-213) by liver microsomes and irreversible binding of reactive intermediates to microsomal proteins. Biochem Pharmacol 1987;36:527–36.PubMedGoogle Scholar
  53. 53.
    Van Maanen JMS, De Ruiter C, De Vries J, Kootstra PR, Gobas F, Pinedo HM. The role of metabolic activation by cytochrome P-450 in covalent binding of VP 16-213 to rat liver and HeLa cell microsomal proteins. Eur J Cancer Clin Oncol 1985;21:1099–106.PubMedGoogle Scholar
  54. 54.
    Sinha BK, Myers CE. Irreversible binding of etoposide (VP 16-213) to deoxyribonucleic acid and proteins. Biochem Pharmacol 1984;33:3725–8.PubMedGoogle Scholar
  55. 55.
    Broggini M, Rossi C, Benfenati E, D'Incalci M, Fanelli R, Gariboldi P. Horseradish peroxidase/hydrogen peroxide-catalyzed oxidation of VP16-213. Identification of a new metabolite. Chem Biol Interact 1985;55:215–24.PubMedGoogle Scholar
  56. 56.
    Haim N, Nemec J, Roman J, Sinha BK. Peroxidecatalyzed metabolism and binding of VP-16 to protein and DNA. Proc Am Assoc Cancer Res 1987;28:301.Google Scholar
  57. 57.
    Aherne GH, Marks V. A radioimmuno-assay for VP 16-213 in plasma. Cancer Chemother Pharmacol 1982;7:117–21.PubMedGoogle Scholar
  58. 58.
    Ho DH, Kanellopoulos KS, Brown NS, Issell BF, Bodey GP. Radioimmunoassay for etoposide and teniposide. J Immunol Methods 1985;85:5–15.PubMedGoogle Scholar
  59. 59.
    Yamashita K, Watanabe K, Takayama H, Ishibashi M, Miyazaki H. Measurement of plasma etoposide by radioimmunoassay. J Pharm Biomed Anal 1987;5:11–20.Google Scholar
  60. 60.
    Hacker MP, Keve S, Ershler WB. Determination of VP 16-213 concentrations using an enzyme linked immunosorbent assay (ELISA). Proc Am Assoc Cancer Res 1984;25:364.Google Scholar
  61. 61.
    Werkhoven-Goewie CE, Brinkman UATh, Frei RW, De Ruiter C, De Vries J. Automated liquid Chromatographic analysis of the anti-tumorigenic drugs etoposide (VP 16-213) and teniposide (VM 26). J Chromatogr 1983;276:349–57.PubMedGoogle Scholar
  62. 62.
    Danigel H, Pfluger K-H, Jungclas H, Schmidt L, Dellbrugge J. Drug monitoring of etoposide (VP 16-213). 1. A combined method of liquid chromatography and mass spectrometry. Cancer Chemother Pharmacol 1985;15:121–4.PubMedGoogle Scholar
  63. 63.
    Duncan GF, Farmen RH, Movahhed HS, Pittman KA. High-performance liquid Chromatographic method for the determination of etoposide in plasma using electrochemical detection. J Chromatogr 1986;380:357–65.PubMedGoogle Scholar
  64. 64.
    Hersh MR, Ludden TM. High-performance liquid Chromatographic assay for etoposide in human plasma. J Pharm Sci 1986;75:815–7.PubMedGoogle Scholar
  65. 65.
    Strife RJ, Jardine I, Colvin M. Analysis of the anticancer drugs etoposide (VP 16-213) and teniposide (VM 26) by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1981;224:168–74.PubMedGoogle Scholar
  66. 66.
    Farina P, Marzillo G, D'Incalci M. High-performance liquid chromatography determination of 4′-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-d-glucopyranoside) (VP 16-213) in human plasma. J Chromatogr 1981;222:141–5.PubMedGoogle Scholar
  67. 67.
    Holthuis JJM, Van Oort WJ, Pinedo HM. A sensitive high-performance liquid chromatographic method for determination of the anti-neoplastic agents VP 16-213 and VM 26 in biological fluids. Anal Chim Acta 1981;130:23–30.Google Scholar
  68. 68.
    Holthuis JJM, Römkens FMGM, Pinedo HM, Van Oort WJ. Plasma assay for the antineoplastic agent VP 16-213 (etoposide) using high-performance liquid chromatography with electrochemical detection. J Pharm Biomed Anal 1983;1:89–97.Google Scholar
  69. 69.
    Harvey VJ, Joel SP, Johnston A, Slevin ML. Highperformance liquid chromatography of etoposide in plasma and urine. J chromatogr 1985;339:419–23.PubMedGoogle Scholar
  70. 70.
    Littlewood TJ, Hutchings AL, Bentley DP, Spragg BP. High-performance liquid Chromatographic determination of etoposide in plasma using electrochemical detection. J Chromatogr 1984;336:434–7.PubMedGoogle Scholar
  71. 71.
    Allen LM. Analysis of 4′-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-Β-d-glucopyranoside) by high pressure liquid chromatography. J Pharm Sci 1980;69:1440–1.PubMedGoogle Scholar
  72. 72.
    Rideout JM, Ayres DC, Lim CK, Peters TJ. Determination of etoposide (VP 16-213) and teniposide (VM 26) in serum by high performance liquid chromatography with electrochemical detection. J Pharm Biomed Anal 1984;2:125–8.Google Scholar
  73. 73.
    Van Opstal MAJ, Blauw JS, Holthuis JJM, Van Bennekom WP, Bult A. On-line electrochemical derivatization combined with diode array UV/VIS in detection in flow injection analysis. Rapid determination of etoposide and teniposide in plasma. Anal Chim Acta 1987;201:35–47.Google Scholar
  74. 74.
    D'Incalci M, Farina P, Sessa C, et al. Pharmacokinetics of VP16-213 given by different administration methods. Cancer Chemother Pharmacol 1982;7:141–5.PubMedGoogle Scholar
  75. 75.
    D'Incalci M, Rossi CR, Zucchetti M, et al. Pharmacokinetics of etoposide in patiients with abnormal renal and hepatic function. Cancer Res 1986;46:2566–71.PubMedGoogle Scholar
  76. 76.
    Cunningham D, McTaggart L, Soukop M, Cummings J, Forrest GJ, Stuart JFB. Etoposide: a pharmacokinetic profile including an assessment of bioavailability. Med Oncol Tumor Pharmacother 1986;3:95–9.PubMedGoogle Scholar
  77. 77.
    Brindley CJ, Antoniw P, Newlands ES, Bagshawe KD. Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma. Cancer Chemother Pharmacol 1985;15:66–71.PubMedGoogle Scholar
  78. 78.
    D'Incalci M, Sessa C, Rossi C, Rovario G, Mangioni C. Pharmacokinetics of etoposide in gestochoriocarcinoma. Cancer Treat Rep 1985;69:69–72.PubMedGoogle Scholar
  79. 79.
    Bennett CL, Sinkule JA, Schilsky RL, Senekjian E, Choi KE. Phase 1 clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res 1987;47:1952–6.PubMedGoogle Scholar
  80. 80.
    Holthuis JJM, Van de Vyver FL, Van Oort WJ, Verleun H, Bekaert AB, De Broe ME. Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. Cancer Treat Rep 1985;69:1279–82.PubMedGoogle Scholar
  81. 81.
    Stewart DJ, Nundy D, Maroun JA, Tetreault L, Prior J. Bioavailability, pharmacokinetics and clinical effects of an oral preparation of etoposide. Cancer Treat Rep 1985;69:269–73.PubMedGoogle Scholar
  82. 82.
    Pfeffer M, Nardella PA, Van Harken DR, et al. The absolute oral bioavailability and pharmacokinetics of etoposide. In: Issell BF, Muggia FM, Carter SK, eds. Etoposide (VP-16) current status and new developments. Orlando: Academic Press Inc., 1984;127–40.Google Scholar
  83. 83.
    Savaraj N, Feun LG, Lu K, Wallace S, Fields WS, Loo TL. Clinical pharmacology of intracarotid etoposide. Cancer Chemother Pharmacol 1986;16:292–4.PubMedGoogle Scholar
  84. 84.
    Zimm S, Cleary SM, Lucas WE, et al. Phase 1. Pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res 1987;47:1712–6.PubMedGoogle Scholar
  85. 85.
    Jones JM, Olman EA, Egorin MJ, Aisner J. A case report and description of the pharmacokinetic behavior of intrapleurally instilled etoposide. Cancer Chemother Pharmacol 1985;14:172–4.PubMedGoogle Scholar
  86. 86.
    Pelsor FR, Allen LM, Creaven PJ. Multicompartment pharmacokinetic model of 4′-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-Β-d-glucopyranoside) in humans. J Pharm Sci 1978;67:1106–8.PubMedGoogle Scholar
  87. 87.
    Creaven PJ. The clinical pharmacology of VM26 and VP16-213. A brief overview. Cancer Chemother Pharmacol 1982;7:133–40.PubMedGoogle Scholar
  88. 88.
    Stewart DJ, Richard M, Hugenholtz H, Dennery J. VP-16 and VM-26 penetration into human brain tumors. Proc Am Assoc Cancer Res 1983;24:133.Google Scholar
  89. 89.
    Nissen NI, Hansen HH, Pedersen H, Stroyer I, Dombernowsky P, Hessellund M. Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease. Cancer Chemother Rep 1975;59:1027–9.PubMedGoogle Scholar
  90. 90.
    Nissen NI, Dombernowsky P, Hansen HH, Larsen V. Phase 1 clinical trial of an oral solution of VP-16-213. Cancer Treat Rep 1976;60:943–5.PubMedGoogle Scholar
  91. 91.
    Lau ME, Hansen HH, Nissen NI, Pedersen H. Phase 1 trial of a new form of an oral administration of VP-16-213. Cancer Treat Rep 1979;63:485–7.PubMedGoogle Scholar
  92. 92.
    Smyth RD, Pfeffer M, Scalzo A, Comis RL. Bioavailability and pharmacokinetics of etoposide (VP-16). Semin Oncol 1985;vnxii(suppl 2):48–51.Google Scholar
  93. 93.
    Harvey VJ, Slevin ML, Joel SP, Johnston A, Wrigley PFM. The effect of dose on the bioavailability of oral etoposide. Cancer Chemother Pharmacol 1986;16:178–81.PubMedGoogle Scholar
  94. 94.
    Harvey VJ, Slevin ML, Joel SP, Johnston A, Wrigley PFM. The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide. Br J Cancer 1985;52:363–7.PubMedGoogle Scholar
  95. 95.
    Anonymous. The United States Pharmacopeia. xxi. Rockville: United States Pharmacopeial Convention, 1985;1424.Google Scholar
  96. 96.
    Sinkule JA, Stewart CF, Crom WR, Melton ET, Dahl GV, Evans WE. Teniposide (VM 26) disposition in children with leukemia. Cancer Res 1984;44:1235–7.PubMedGoogle Scholar
  97. 97.
    D'Incalci M, Rossi C, Sessa C, et al. Pharmacokinetics of teniposide in patients with ovarian cancer. Cancer Treat Rep 1985;69:73–7.PubMedGoogle Scholar
  98. 98.
    Holthuis JJM, De Vries EGE, Postmus PE, et al. Pharmacokinetics of high-dose teniposide. Cancer Treat Rep 1987;71:599–603.PubMedGoogle Scholar
  99. 99.
    Canal P, Bugat R, Michel C, Roche H, Soula G, Combes PF. Pharmacokinetics of teniposide (VM 26) after i.v. administration in serum and malignant ascites of patients with ovarian carcinoma. Cancer Chemother Pharmacol 1985;15:149–52.PubMedGoogle Scholar
  100. 100.
    Stewart DJ, Richard MT, Hugenholtz H, et al. Penetration of teniposide (VM 26) into human intracerebral tumors. J Neuro-Oncol 1984;324:315–24.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1988

Authors and Affiliations

  • J. J. M. Holthuis
    • 1
  1. 1.Department of Pharmaceutical Analysis, Faculty of PharmacyState University of UtrechtGH Utrechtthe Netherlands

Personalised recommendations